Looking to Invest in the Next Big Craze Like Ozempic? This 1 Emerging Field Could Be It.
https://www.fool.com/investing/2023/12/21/looking-to-invest-in-next-big-craze-like-ozempic/?source=iedfolrf0000001
Dec 21, 2023 - Diabetes and weight-loss drugs won't be the hottest category of medicines forever.
0
Why Novo Nordisk Stock Was Up on a Down Day for the Market
https://www.fool.com/investing/2023/12/20/why-novo-nordisk-stock-was-up-on-a-down-day-for-th/?source=iedfolrf0000001
Dec 20, 2023 - As if the company's top two products weren't popular enough, a new media report made them even more appealing.
0
FDA Accepts Merck's (MRK) BLA for 21-Valent Pneumococcal Jab
https://www.zacks.com/stock/news/2200645/fda-accepts-merck-s-mrk-bla-for-21-valent-pneumococcal-jab?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2200645
Dec 20, 2023 - The FDA grants priority review to Merck's (MRK) filing seeking approval for its 21-valent pneumococcal conjugate vaccine in adults. A final decision is expected in June 2024.
0
4 Drug Stocks Rising More Than 40% in 2023 With Room to Grow
https://www.zacks.com/stock/news/2200461/4-drug-stocks-rising-more-than-40-in-2023-with-room-to-grow?cid=CS-ZC-FT-analyst_blog|investment_ideas-2200461
Dec 20, 2023 - Novo Nordisk (NVO), Journey Medical Corporation (DERM), Lyra Therapeutics (LYRA) and Fusion Pharmaceuticals (FUSN) have returned 40% or higher year to date and have room for more growth in 2024.
0
Pfizer (PFE) Stock Rises on FDA Nod for Expanded Use of Padcev
https://www.zacks.com/stock/news/2200049/pfizer-pfe-stock-rises-on-fda-nod-for-expanded-use-of-padcev?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2200049
Dec 19, 2023 - The FDA approves Pfizer's (PFE) Padcev in combination with Merck's (MRK) Keytruda for adult patients with advanced bladder cancer. Stock rises 1.6%.
0
Merck (MRK) Gets EU Nod for Expanded Use in Gastric Cancer
https://www.zacks.com/stock/news/2200047/merck-mrk-gets-eu-nod-for-expanded-use-in-gastric-cancer?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2200047
Dec 19, 2023 - Following these approvals, Merck's (MRK) Keytruda is approved for seven gastrointestinal cancers in the European Union. Overall, the drug is approved for 26 indications in the region.
0
Alexandria (ARE) Inks Leases at its Campuses Amid Solid Demand
https://www.zacks.com/stock/news/2200025/alexandria-are-inks-leases-at-its-campuses-amid-solid-demand?cid=CS-ZC-FT-analyst_blog|company_news_-_finance_sector-2200025
Dec 19, 2023 - Amid the booming demand for life-science assets, Alexandria (ARE) inks leases with Novo Nordisk and CARGO at its mega campuses in Greater Boston and San Carlos in the San Francisco Bay Area.
0
These Are the 3 Hottest Biopharma Trends of 2024. Should You Invest?
https://www.fool.com/investing/2023/12/18/these-are-the-3-hottest-biopharma-trends-of-2024/?source=iedfolrf0000001
Dec 18, 2023 - 2024 is going to be a sizzler in the biopharma sector.
0
5 Big Drug Stocks That May Continue to Outperform in 2024
https://www.zacks.com/stock/news/2199316/5-big-drug-stocks-that-may-continue-to-outperform-in-2024?cid=CS-ZC-FT-analyst_blog|investment_ideas-2199316
Dec 18, 2023 - Novo Nordisk (NVO), Eli Lilly (LLY), Vertex Pharmaceuticals (VRTX), Regeneron (REGN) and GSK (GSK) have been performing well this year. These stocks are poised to keep the momentum alive in 2024.
0
5 Non-U.S. Stocks to Buy as Wall Street Fires on All Cylinders
https://www.zacks.com/stock/news/2199250/5-non-u-s-stocks-to-buy-as-wall-street-fires-on-all-cylinders?cid=CS-ZC-FT-analyst_blog|investment_ideas-2199250
Dec 18, 2023 - We have selected five high-flying non-U.S. companies that have strong potential for 2024. These are: NVO, NTES, TM, PDD, STLA.
0